Pierre Raymond Bourque

Pierre Raymond Bourque

Auto-generated profile, based on publicly available information

Pierre Raymond Bourque

Division of Neurology, Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ontario, Canada

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
PBP R Bourque
P R Bourque
CPC E Pringle
C E Pringle
WCW Cameron
W Cameron
JCJuthaporn Cowan
Juthaporn Cowan
JCJ Warman Chardon
J Warman Chardon
Immunoglobulin therapy has become a major treatment option in several autoimmune neuromuscular disorders. For patients with Myasthenia Gravis (MG), intravenous immunoglobulin (IVIg) has been used for both crisis and chronic management. Subcutaneous Immunoglobulins (SCIg), which offer the advantage of home administration, may be a practical and effective option in chronic management of MG. We analyzed clinical outcomes and patient satisfaction in nine cases of chronic disabling MG who were either transitioned to, or started de novo on SCIg. This was a retrospective cohort study for the period of 2015–2016, with a mean follow-up period of 6.8 months after initiation of SCIg. All patients with MG treated with SCIg at the Ottawa Hospital, a large Canadian tertiary hospital with subspecialty expertise in neuromuscular disorders were included, regardless of MG severity, clinical subtype and antibody status. The primary outcome was MG disease activity after SCIg initiation. This outcome was measured by 1) the Myasthenia Gravis Foundation of America (MGFA) clinical classification, and 2) subjective scales of disease activity including the Myasthenia Gravis activities of daily living profile (MG-ADL), Myasthenia Gravis Quality-of-life (MG-QOL 15), Visual Analog (VA) satisfaction scale. We also assessed any requirement for emergency department visits or hospitalizations. Safety outcomes included any SCIg related complication. All patients were stable or improved for MGFA class after SCIg initiation. Statistically significant improvements were documented in the MG-ADL, MG-QOL and VAS scales. There were no exacerbations after switching therapy and no severe SCIg related complications. SCIg may be a beneficial therapy in the chronic management of MG, with favorable clinical outcome and patient satisfaction results.

3 December 2019 in Neurology
Verified
Journal Article
Closed access
PDF file
JZJocelyn Zwicker
Jocelyn Zwicker
DQDanial Qureshi
Danial Qureshi
RTRobert Talarico
Robert Talarico
PBPierre Bourque
Pierre Bourque
MSMary Scott
Mary Scott
PTPeter Tanuseputro
Peter Tanuseputro
Objective To describe health care service utilization and cost for decedents with and without amyotrophic lateral sclerosis (ALS) in the last year of life. Methods Using linked health administrative data, we conducted a retrospective, population-based cohort study of Ontario, Canada, decedents from 2013 to 2015. We examined demographic data, rate of utilization, and cost of health care services in the last year of life. Results We identified 283,096 decedents in Ontario, of whom 1,212 (0.42%) had ALS. Decedents with ALS spent 3 times as many days in an intensive care unit (ICU) (mean 6.3 vs 2.1, p < 0.001), and twice as many days using complex continuing care (mean 12.7 vs 6.0, p < 0.001) and home care (mean 99.1 vs 41.3, p < 0.001). A greater percentage of decedents with ALS received palliative home care (44% vs 20%, p < 0.001) and palliative physician home visits (40% vs 18%, p < 0.001) than decedents without ALS. Among decedents with ALS, a palliative physician home visit in the last year of life was associated with reduced adjusted odds of dying in hospital (odds ratio 0.65, 95% confidence interval 0.48–0.89) and fewer days spent in the ICU. Mean cost of care in the last year of life was greater for those with ALS ($68,311.98 vs $55,773.48, p < 0.001). Conclusions In this large population-based cohort of decedents, individuals with ALS spent more days in the ICU, received more community-based services, and incurred higher costs of care in the last year of life. A palliative care physician home visit was associated with improved end of life outcomes; however, the majority of patients with ALS did not access such services.

1 August 2018 in Neurology Genetics
Verified
Journal Article
Open access
PDF file
PBPierre R. Bourque
Pierre R. Bourque
JWJodi Warman-Chardon
Jodi Warman-Chardon
DLDaniel A. Lelli
Daniel A. Lelli
LLLauren LaBerge
Lauren LaBerge
CKCarly Kirshen
Carly Kirshen
KBKym M. Boycott
Kym M. Boycott

16 November 2019 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
PBPierre R. Bourque
Pierre R. Bourque
JBJ. Brooks
J. Brooks
JWJ. Warman-Chardon
J. Warman-Chardon
ABA. Breiner
A. Breiner

1 January 2019 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
PBPierre R. Bourque
Pierre R. Bourque
ABAri Breiner
Ari Breiner
DMDavid Moher
David Moher
JBJohn Brooks
John Brooks
HHHarald Hegen
Harald Hegen
CMChristopher R. McCudden
Christopher R. McCudden

15 November 2013 in Journal of Clinical Monitoring and Computing
Verified
Journal Article
Open access
PDF file
DHDavid A. Houlden
David A. Houlden
CTChantal A. Turgeon
Chantal A. Turgeon
TPThomas Polis
Thomas Polis
JSJohn Sinclair
John Sinclair
SCStuart Coupland
Stuart Coupland
AKAmin Kassam
Amin Kassam
Flash visual evoked potentials (FVEPs) are often irreproducible during surgery. We assessed the relationship between intraoperative FVEP reproducibility and EEG amplitude. Left then right eyes were stimulated by goggle light emitting diodes, and FVEPs were recorded from Oz–Fz′ (International 10-20 system) in 12 patients. Low cut filters were ≤5 Hz in all patients; two patients also had recordings using 10 and 30 Hz. The reproducibility of FVEP and the amplitude of the concomitant EEG from C4′–Fz were measured. Nine patients had low amplitude EEG (50 μV); FVEPs were absent from three of four eyes with normal pre-operative vision (the other normal eye had a present but irreproducible FVEP). Raising the low cut filter to 10 and 30 Hz (in two patients) progressively reduced EEG and FVEP amplitude, reduced amplifier blocking time and improved FVEP reproducibility. FVEPs were more reproducible in the presence of low amplitude EEG than high amplitude EEG. This is the first report describing the effect of EEG amplitude on FVEP reproducibility during surgery.